Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer
December 20 2023 - 4:15PM
Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the
“Company”), a life science company committed to realizing the
potential of mRNA cell engineering to provide patients with
transformational new medicines, has appointed Sanjeev Luther as
President and Chief Executive Officer and a member of the company's
Board of Directors, effective January 1, 2024. Mr. Luther will
replace Matt Angel, Ph.D., the current President and Chief
Executive Officer.
James Bristol, Ph.D., Chairman of Eterna’s Board of Directors,
said, “We are excited to have Sanjeev take on the role of President
and CEO of Eterna as we continue our work to support the
development of next-generation therapies using mRNA cell
engineering. Sanjeev has an impressive track record in leadership,
strategic planning, and business development across various global
organizations in the pharmaceutical and healthcare sectors. The
Board looks forward to working with Sanjeev as Eterna continues to
capitalize on its in-licensed portfolio of patented mRNA cell
engineering technologies.”
Mr. Luther stated, “It’s an honor to join Eterna’s team at this
exciting time. I look forward to working closely with Eterna's
scientists, management team, and Board to deliver sustained value
to our shareholders and to further the reach and promise of mRNA
cell engineering.”
Mr. Luther is a seasoned pharmaceutical executive having spent
over 30 years in leadership roles across public and private
biotechnology and global pharmaceutical companies. Most recently,
he served as President, CEO, and Board Member of Cornerstone
Pharmaceuticals, where he oversaw the evolution of the company’s
pipeline for rare cancers and secured strategic partnership,
in-licensing, and out-licensing agreements. At Cornerstone, he also
held the roles of Chief Operations Officer and Chief Business
Officer.
Prior to Cornerstone, Mr. Luther led business-building and
fundraising strategies for Fortune 500 corporations and start-ups
in pharmaceuticals, biotech, medical devices, and diagnostics,
including Bristol-Myers Squibb, Novartis, Bausch and Lomb, and GE
Healthcare. He has experience across a range of therapeutic areas
and stages, from R&D through commercialization. Mr. Luther
holds an MBA in Marketing and a B.S. in Marketing/Business
Administration from the State University of New York at
Buffalo.
About Eterna Therapeutics Inc.Eterna
Therapeutics is a life science company committed to realizing the
potential of mRNA cell engineering to provide patients with
transformational new medicines. Eterna has in-licensed a portfolio
of over 130 patents covering key mRNA cell engineering
technologies, including technologies for mRNA cell reprogramming,
mRNA gene editing, the NoveSlice™ and UltraSlice™ gene-editing
proteins, and the ToRNAdo™ mRNA delivery system from Factor
Bioscience. NoveSlice™, UltraSlice™, and ToRNAdo™ are trademarks of
Factor Bioscience. For more information, please
visit www.eternatx.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, which are intended
to be covered by the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are any statements that are not statements of historical
fact and may be identified by terminology such as “believe,”
“could,” “estimate,” “anticipate,” “expect,” “plan,” “possible,”
“potential,” “project,” “will” or other similar words and the
negatives of such words. Forward-looking statements are based on
current beliefs and assumptions that are subject to risks and
uncertainties and are not guarantees of future performance. Actual
results could differ materially from those stated or implied in any
forward-looking statement as a result of various factors,
including, but not limited to, uncertainties related to: (i) the
evolution of Eterna’s business model into a platform company
focused on mRNA, induced pluripotent stem (iPS) cell and gene
editing technologies; (ii) Eterna’s ability to successfully,
cost-effectively and efficiently develop its technology and
products; (iii) Eterna’s ability to successfully commence clinical
trials of any products on a timely basis or at all; (iv) Eterna’s
ability to successfully fund and manage the growth of its
development activities; and (v) Eterna’s ability to obtain
regulatory approvals of its products for commercialization. You
should not rely upon forward-looking statements as predictions of
future events. The forward-looking statements made in this
communication speak only as of the date on which they were made,
and Eterna does not undertake any obligation to update the
forward-looking statements contained herein to reflect events that
occur or circumstances that exist after the date hereof, except as
required by applicable law. Factors that may cause Eterna’s actual
results to differ from those expressed or implied in
forward-looking statements contained in this press release are more
fully disclosed in Eterna’s periodic public filings with the U.S.
Securities and Exchange Commission, particularly under the heading
“Risk Factors” in Eterna’s Annual Report on Form 10-K for the year
ended December 31, 2022, as well as under similar headings in
Eterna’s subsequently filed Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K.
Investor Relations
Contact:investors@eternatx.com
Media Contact:EternaPR@westwicke.com
Eterna Therapeutics (NASDAQ:ERNA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Eterna Therapeutics (NASDAQ:ERNA)
Historical Stock Chart
From Oct 2023 to Oct 2024